CALI: CalciMedica Inc Price to Sales
CalciMedica, Inc. (CALI) operates as a biopharma startup, investing all capital into research without generating revenue. The price-to-sales multiple clearly demonstrates this lack of sales, where the level of 0.00 is the current value. Geopolitical tensions and sanctions complicate the logistics of biomaterials, yet professional management is successfully adapting the company's structure based on the results of anti-inflammatory drug trials.
Analytical breakdowns for CalciMedica Inc (CALI)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
CALI - Net Profit|Net Profit Forecast CalciMedica, Inc.|CALI - P/E Multiple|Market Cap to Projected Earnings CalciMedica|CALI - PEG Multiple|Enterprise Value to EBITDA Ratio CALI|CALI - Operating profit EBITDA|Net earnings per share (EPS TTM) CalciMedica|CALI - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months calcimedica.com|CALI - Earnings growth in current year|Consensus forecast of earnings per share growth for next year CalciMedica, Inc.
- issuer revenue and sales details:
General company analysis:CALI, CalciMedica, Inc.
The multiple compares the market value of CalciMedica, Inc. (CALI) to its sales volume, allowing for an assessment of the asset's overvaluation relative to its generated cash flow. For the biotech sector, characterized by high patent scalability, this price-to-sales ratio reflects market expectations for the global implementation of the therapy, helping investors timely identify the risk of purchasing an overvalued business.
Competitors of CalciMedica, Inc.
argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple AKTX (Akari Therapeutics, Plc)|P/S Multiple enlivex.com ENLV|QTTB: Market Cap to Revenue|GOVX - P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Revenue Ratio|IBIO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio carismatx.com|XTLB: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Revenue Ratio|Price-to-Revenue Ratio aptevotherapeutics.com APVO|AIM - Market Cap to Revenue|Aditxt - P/S Multiple|Price-to-Revenue Coefficient GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Revenue Ratio|Price to Sales reshapelifesciences.com (HIND)|Price-to-Revenue Ratio Revelation Bio|Price to Sales Indaptus Therapeutics, Inc. INDP|Price-to-Revenue Ratio BiondVax Pharmaceuticals (SCNI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple
